Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review
Xu Jing, Wang Min, Liu Xia, Li Shanshan
TL;DR
This case report shows that ruxolitinib, a JAK1/2 inhibitor, improved symptoms in an adult dermatomyositis patient with anti-TIF1γ antibody and JAK2 mutation.
Contribution
The paper presents a novel case of ruxolitinib use in adult-onset dermatomyositis with anti-TIF1γ and JAK2 V617F mutation.
Findings
The patient's dermatomyositis symptoms improved significantly with ruxolitinib treatment.
The patient's platelet count remained stable despite treatment.
The paper summarizes existing literature on ruxolitinib in adult DM and JAK2 V617F mutations.
Abstract
Ruxolitinib is a selective JAK1/2 inhibitor, and its application in treating adult-onset dermatomyositis(DM) has rarely been described. Here, we report a case of an adult-onset DM patient with anti-TIF1γ antibody, who also suffered from essential thrombocytosis related to the JAK2 V617F mutation. Her clinical symptoms of DM markedly improved after ruxolitinib treatment, whereas her platelet count did not significantly change. In addition, we reviewed previous studies on the treatment of adult DM with ruxolitinib, and summarized reports of the JAK2 V617F mutation in adult idiopathic inflammatory myopathy.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsInflammatory Myopathies and Dermatomyositis · Eosinophilic Disorders and Syndromes · Dermatological and Skeletal Disorders